

# BD, Biocorp Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs

**Companies to Explore Opportunities to Integrate Biocorp's Injay® Technology with BD UltraSafePlus™ Passive Needle Guard to Help Biopharmaceutical Manufacturers Capture and Transmit Self-Administered Injection Data.**

**FRANKLIN LAKES, N.J. (October 17, 2022)** – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp, a medical device and delivery systems manufacturer based in France, today announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics.

To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay® technology – a solution designed to capture and transmit injection events using Near Field Communication (NFC) technology – to the BD UltraSafe Plus™ Passive Needle Guard used with prefillable syringes.

“Connected drug delivery devices play an important role in helping biopharmaceutical manufacturers understand and track key trends in patient adherence,” said Matthew Schabacker, vice president and general manager of Advanced Drug Delivery Solutions at BD. “Our agreement with BioCorp enables us to explore innovative solutions in this market and further supports BD's commitment to smart, connected care, enabling care to transition to alternate settings and improving chronic disease outcomes — as we combine Biocorp's expertise in developing and commercializing connected drug delivery devices to our existing portfolio of advanced injection drug delivery systems.”

Biocorp's Injay® is a simple and cost-effective connected solution designed to monitor the use of pre-fillable syringes in clinical studies or routine care. Through NFC technology and specific sensors to identify the product, it can confirm a complete injection and easily transfer that information to a smartphone.

“We are very proud to announce this collaboration with BD, a worldwide leader in pre-filled syringes and safety device market,” said Eric Dessertenne, CEO of Biocorp. “It shows the leading position of Biocorp in the field of smart drug delivery devices and addresses an unmet need in the market today.”

The increased prevalence of self-administered therapies for chronic diseases coupled with the pervasiveness of digital technologies in everyone's life open new opportunities to improve outcomes and experience for patients and to increase the ability to monitor medication adherence.

The global connected drug delivery market is expected to grow at double digit growth rates<sup>1</sup> over the next decade – fueled by the transition from acute care settings to home care and the increased prevalence of self-administered therapies. Today, BD is a world leader in supplying prefillable syringes and safety systems to the biopharmaceutical industry – with approximately 70 percent of the top 100 biopharmaceutical companies using BD devices, and more than one billion BD UltraSafe™ units<sup>2</sup> sold since 2010 being used to administer over 40 different drugs.<sup>3</sup>

## About Pre-Fillable Syringes

Prefillable syringes (PFS) are an important option in the packaging and delivery of injectable drug products, including vaccines, biologics and anticoagulants. PFS help enable the administration of a drug in two ways. First, a PFS is a drug delivery system designed to administer the appropriate amount of the drug to the patient both safely and reliably. Second, PFS packaging helps assure that there are no adverse effects on the quality, purity or potency of the drug over its full shelf life.

## About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next

generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit [bd.com](https://www.bd.com) or connect with us on LinkedIn at [www.linkedin.com/company/bd1/](https://www.linkedin.com/company/bd1/) and Twitter [@BDandCo](https://twitter.com/BDandCo).

#### **Contacts:**

##### Media:

Trey Hollern  
Director, Public Relations  
862.284.8629  
[trey.hollern@bd.com](mailto:trey.hollern@bd.com)

##### Investors:

Francesca DeMartino  
SVP, Head of Investor Relations  
201.847.5743  
[Francesca.demartino@bd.com](mailto:Francesca.demartino@bd.com)

#### **About Biocorp**

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCOP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCOP's product portfolio of innovative connected solutions. The company has 75 employees. BIOCOP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit [www.biocorpsys.com](https://www.biocorpsys.com).

#### **Contacts:**

Sylvaine Dessard  
Marketing & Communication Director  
[rp@biocorp.fr](mailto:rp@biocorp.fr)

Bruno ARABIAN  
[barabian@ulyse-communication.com](mailto:barabian@ulyse-communication.com)  
+33 (0)6 87 88 47 26

---

<sup>1</sup> [Grandview Research CDDD Market](#), [Data Bridge Market Research Global CDDD Market](#)

<sup>2</sup> As of 2020

<sup>3</sup> Drug products approved with BD UltraSafe™ solutions. Includes both BD UltraSafe Passive™ and BD UltraSafe Plus™ passive needle guards

---

<https://news.bd.com/2022-10-17-BD,-Biocorp-Sign-Agreement-to-Bring-Connectivity,-Traceability-to-Self-Administered-Injectable-Drugs>